In contrast, while Guery et al. confirmed that 30% of all AML patients expressed CD276, they did not find an increased expression in CD34+CD38- cells and documented a significantly improved event-free survival in patients with CD276+ AML [80]. This evidence concerns the gene CD34 and acute myeloid leukemia.